Otenabant

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Otenabant
Otenabant.svg
Systematic (IUPAC) name
1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-(ethylamino)piperidine-4- carboxamide
Clinical data
Legal status ?
Identifiers
CAS number 686344-29-6 YesY
ATC code None
PubChem CID 10052040
ChemSpider 8227602 N
UNII J8211Y53EF N
KEGG D09362 YesY
ChEMBL CHEMBL562668 N
Chemical data
Formula C25H25Cl2N7O 
Mol. mass 510.4 g/mol
 N (what is this?)  (verify)

Otenabant (CP-945,598) is a drug which acts as a potent and highly selective CB1 antagonist.[1] It was developed by Pfizer for the treatment of obesity,[2] but development for this application has been discontinued following the problems seen during clinical use of the similar drug rimonabant.[3]

See also[edit]

References[edit]

  1. ^ Kim, M., et al. (2008), "Design, chemical synthesis, and biological evaluation of novel triazolyl analogues of taranabant (MK-0364), a cannabinoid-1 receptor inverse agonist", Tetrahedron 64 (48): 10802–10809, doi:10.1016/j.tet.2008.09.057 
  2. ^ Woods SC. The endocannabinoid system: novel pathway for cardiometabolic Risk-factor reduction. Journal of the American Academy of Physician Assistants. 2007 Nov;Suppl Endocannabinoid:7-10. PMID 18047036
  3. ^ http://www.pfizer.com